Viokace market seen expanding on rising pancreatic disease demand
The Viokace market is projected to grow through 2026 as more patients are diagnosed with exocrine pancreatic insufficiency and other pancreatic disorders. North America leads today, while aging populations, higher health spending and wider use of enzyme replacement therapies are expected to support demand worldwide.
Why it matters: - Viokace demand is tied to the growing need for prescription enzyme replacement therapy in patients with exocrine pancreatic insufficiency. - The market outlook matters because pancreatic disorders are becoming more common, especially as populations age and chronic disease rates rise. - Wider access to treatment could improve digestion, nutrient absorption and quality of life for patients with long-term pancreatic disease.
What happened: - The Business Research Company published its Viokace Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Viokace market is gaining attention as digestive health becomes a larger global concern. - The report includes a free sample download for the Viokace market report. - The full report is available here.
The details: - Viokace is a prescription drug containing pancrelipase. - Viokace is used as enzyme replacement therapy for exocrine pancreatic insufficiency. - The therapy supports patients with chronic pancreatitis, cystic fibrosis and other disorders that reduce the pancreas’s ability to make digestive enzymes. - Viokace helps digest fats, proteins and carbohydrates. - The drug is intended to improve nutrient absorption and reduce symptoms such as malabsorption and weight loss. - The report points to diagnosis gains, higher chronic pancreatitis incidence, better enzyme formulation stability, more clinician awareness of malabsorption disorders and wider use of prescription enzyme therapies as past growth drivers. - Future growth is expected to come from demand for long-term digestive support, personalized dosing, an aging population, nutrition optimization and broader access to specialized gastrointestinal therapies. - The report highlights rising use of enzyme replacement treatments, stronger focus on digestive disorder management, more pancreatic enzyme supplement use, expanded chronic pancreatitis treatment protocols and better patient adherence programs. - The market analysis covers North America, Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - In 2025, North America held the largest share of the Viokace market.
Between the lines: - Rising pancreatic cancer and pancreatic disorder prevalence is expanding the addressable patient pool for enzyme replacement therapies. - The report cites Cancer Research UK projections from February 2023 showing pancreatic cancer incidence in the UK rising 5% between 2023-2025 and 2038-2040, reaching 19 cases per 100,000 people annually by 2038-2040. - An aging population is strengthening demand because older adults are more likely to face digestive issues tied to pancreatic insufficiency or chronic disease. - The report cites UN Department of Economic and Social Affairs data from 2024 showing that in 2023 ten least developed countries had over one million older adults, with projections for 27 such countries by 2050. - Higher healthcare spending can make advanced therapies more available through better infrastructure and reimbursement systems. - The report cites UK Office for National Statistics data showing total healthcare expenditure rose 5.6% nominally from 2022 to 2023, after 0.9% growth in 2022. - The company is positioning the report around broader strategic tools, including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards and market hotspots infographics.
What's next: - Demand is expected to keep rising as diagnosis improves and more patients receive treatment for pancreatic insufficiency. - Emerging markets in Asia-Pacific and other regions are expected to add to growth in the coming years. - The report says future adoption will likely be shaped by broader use of personalized dosing and better patient adherence programs. - The Business Research Company provides contact details for expert inquiries through Saumya Sahay and lists the company’s website and social media channels.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthy Living Europe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.